InvestorsHub Logo
Followers 3
Posts 100
Boards Moderated 0
Alias Born 09/02/2011

Re: None

Thursday, 06/02/2016 10:29:59 AM

Thursday, June 02, 2016 10:29:59 AM

Post# of 166

I think we are moving upwards a little because of Sarepta's news.


Sarepta Therapeutic's (NASDAQ: SRPT) 11% LOWER; Jefferies analyst, Gena Wang, hosted a call with FDA regulatory expert Dr. Brian Harvey on the PDUFA postponement for Sarepta Therapeutic's (NASDAQ: SRPT) eteplirsen. Involvements of senior FDA officials could be the reason for the delay and he says approval based on weak data could lead to significant consequences including perceived inconsistency and shift in future trial design. The analyst sees a slim chance of approval given a likely data driven decision by the FDA under current laws.

http://www.streetinsider.com/Special+Reports/Pre-Open+Stock+Movers+0602%3A+%28BWEN%29+%28RPRX%29+%28CIEN%29+Higher%3B+%28CONN%29+%28SRPT%29+%28DV%29+Lower+%28more...%29/11701124.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PTCT News